78 results about "Squamous carcinoma" patented technology

The invention discloses a lung squamous cell carcinoma survival prediction method and system based on SHAP interpretability, and relates to the technical field of medical data analysis. Comprising the following steps: constructing a dynamically updated physiological feature information table based on a lung squamous cell carcinoma clinical data set of a target under multiple time nodes; and associating different survival analysis models with the physiological feature information table to predict the survival probability of the lung squamous cell carcinoma in the target body, the marginal contribution of each input feature to the output of each model is obtained by using the SHAP interpretation algorithm, and the feature uniqueness score is transparently displayed in the fusion process, so that the survival probability of the lung squamous cell carcinoma in the target body can be predicted in the actual use process. The method can visually understand how each feature affects the final prediction, and achieves automatic arbitration or manual recheck through providing a model to explain conflict measurement, invalid variable elimination and pseudo high risk verification and weighted scoring, thereby guaranteeing the reasonability and safety of prediction and intervention suggestions, reducing the decision risk, and enhancing the clinical trust.

The invention discloses a lung squamous cell carcinoma drug discovery method and system based on disturbance response scanning analysis, and belongs to the field of biological medicines.The method comprises the steps that lung squamous cell carcinoma protein expression profile data is downloaded and preprocessed, a robust network module is constructed and multi-scale analysis and evaluation are conducted, and drug genomic data are obtained based on drug genomic data. Predicting the drug sensitivity of the patient by using machine learning, and generating a DRN through difference analysis of the drug sensitivity; predicting drug-target protein binding affinity in combination with deep learning, quantifying node sensitivity through a PRS technology, calculating a DPI disturbance score and ranking drug priorities; high-ranking drugs are screened through comprehensive sensitivity analysis and literature investigation; a drug for a lung squamous carcinoma cell line is screened out through a pre-experiment and is relocated. According to the framework developed by the invention, by integrating proteomics, pharmacogenomics and dynamic network analysis, systematic analysis is provided for relocation drug identification of lung squamous cell carcinoma, and good news is brought to treatment of lung squamous cell carcinoma.

The invention belongs to the technical field of biological medicine, and provides CKS1B serving as an immunotherapy response prediction biomarker and application of the CKS1B, and according to the application, CKS1B serves as an immunotherapy response marker, and a CKS1B inhibitor is combined with an active component to treat a model mouse. In-vitro cell experiments are adopted to evaluate the immunotherapy prediction effect of the CKS1B as a biomarker on esophageal squamous carcinoma, a Cks1b overexpression tumor mouse model, a homologous mouse model and a human immune reconstruction mouse model are established, and a CKS1B inhibitor is combined with active ingredients to treat the two models; results show that the CKS1B inhibitor combined with the active component can promote removal of esophageal squamous carcinoma cells by CD8 + T cells, inhibit interferon signal channels and antigen presentation, effectively recover immune response, inhibit tumor cell proliferation and significantly reduce tumor volume, so as to achieve the purpose of treating esophageal squamous carcinoma.

The invention relates to the technical field of medical image processing and intelligent grading recognition of tumors, and discloses a head and neck squamous cell carcinoma early recognition method based on radiomics and deep learning, which comprises the following steps: acquiring head and neck CT (Computed Tomography), MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) three-mode image data; a two-stage dynamic structure alignment mechanism is adopted for registration; extracting fusion radiomics features; constructing a tumor sub-feature map; outputting a tumor level and a prediction confidence coefficient through the uncertainty prediction model; and generating a saliency interpretation heat map. In the prior art, a single-mode image or a superficial layer texture feature extraction model is depended on, and especially under the condition that a heterogeneity tumor region boundary is fuzzy and different modes have significant structure offset, high-confidence accurate discrimination of a real staging state of a tumor cannot be realized. According to the method, the accuracy of early stage identification of the head and neck squamous cell carcinoma is improved by introducing the significance guide registration mechanism and the improved graph convolutional neural network and combining Dropout reasoning.

The embodiment of the invention provides a training method of an esophageal squamous carcinoma risk prediction model, and an esophageal squamous carcinoma risk prediction method and system, and belongs to the technical field of medical treatment. According to the scheme, a training feature set is obtained, global importance analysis is carried out on the training feature set through a plurality of different feature selection algorithms, and an importance scoring result of each feature selection algorithm and consensus feature results of all the feature selection algorithms are obtained; performing screening processing according to each importance scoring result to obtain a feature subset corresponding to each feature selection algorithm; inputting each feature subset into a plurality of different classifier algorithms for training to obtain a corresponding basic model; a plurality of high-performance models are screened out from all the basic models through a multi-criterion decision classification fusion framework for weighted fusion, input features after model fusion are determined according to consensus feature results, an esophageal squamous cell carcinoma risk prediction model is obtained, the accuracy of esophageal squamous cell carcinoma risk prediction can be improved, and potential patients can be found in advance.

The application discloses a kind of partition delivery environment response type hydrogel microneedle and its preparation method and application in oral squamous carcinoma treatment.The hydrogel microneedle includes backing layer and the needle tip layer being arranged on the surface of the backing layer, the needle tip layer includes multiple array distribution microneedle tip body, each the needle tip body is connected with the backing layer respectively;Wherein, the backing layer has enzyme response, and the needle tip layer has acidic pH response.The microneedle uses innovative "integration partition design", and two hydrogels with different functions are integrated in single microneedle array: backing layer responds oral flora imbalance microenvironment, needle tip layer responds tumor weak acidic microenvironment.The design can realize partition, accurate, intelligentized synergistic treatment to oral mucosa surface and deep tumor tissue, so as to overcome the technical bottleneck of traditional dosage form in space selectivity, single drug type, release behavior uncontrollable and great systemic toxicity etc.

The invention discloses a biomarker for accurate typing of esophageal squamous carcinoma lesion and application of the biomarker, and belongs to the technical field of molecular biology, the biomarker is SOX2 protein and KDM4B protein which are co-localized in nuclei, and the biomarker is applied to accurate typing of esophageal squamous carcinoma lesion with a non-diagnostic purpose. The cell proportion and distribution conditions of the SOX2 protein and the KDM4B protein are simultaneously displayed on the same section by adopting a double-label immunofluorescence method, and tests prove that the intranuclear co-localization of the SOX2 and the KDM4B can be used as an early warning mark and is used for identifying high-risk patients or early stages of precancerous lesions or distinguishing tumor patients, so that the missed diagnosis rate is reduced, and the diagnosis time is shortened. Therefore, a reliable basis is provided for accurate typing of esophageal squamous carcinoma lesions.

The invention relates to the technical field of biological medicine, and relates to a polypeptide in targeted combination with SOX2 protein and application thereof, the polypeptide has an amino acid sequence as shown in SEQ ID NO.1, or has at least 85%, 90%, 95% or more than 99% of sequence identity with the amino acid sequence; the polypeptide inhibits phase separation of SOX2, liquid drops formed by phase separation of SOX2 can be avoided, then the situation that the liquid drops wrap chemotherapeutic drugs, influence the curative effect of the chemotherapeutic drugs and cause tolerance of tumor cells to the chemotherapeutic drugs is avoided, and the polypeptide does not influence the transcription activation function of SOX2 serving as a transcription factor; the polypeptide can inhibit the phase separation of the SOX2, so that the regulation of normal physiological functions, such as high expression in organs such as eyes of a human body, of the SOX2 as a transcription factor is not influenced, and therefore, the polypeptide disclosed by the invention can reverse chemotherapy drug resistance of tumors such as squamous carcinoma by inhibiting the phase separation of the SOX2, can be used for adjuvant therapy of the tumors such as squamous carcinoma, and has no obvious toxic or side effect on each organ of an organism.

The invention provides an application of ginkgetin in enhancing VS4718 or ponatinib in resisting the progress of esophageal squamous cell carcinoma. It is found that ginkgo biflavone can enhance the growth and invasion inhibition effect of VS4718 or ponatinib on esophageal squamous carcinoma cells; ginkgo biflavone is used for enhancing the inhibition effect of VS4718 or ponatinib on glycolipid metabolism of tumor cells, and the ginkgo biflavone is respectively combined with VS4718 or ponatinib to generate a synergistic anti-cancer effect.

The invention discloses a novel fusobacterium strain Fusobacteria sp.HPSCC05 and an application of the novel fusobacterium strain Fusobacteria sp.HPSCC05. The preservation number of the novel fusobacterium strain Fusobacteria sp.HPSCC05 is CCTCC (China Center For Type Culture Collection) NO: M2025588. According to the invention, Fusobacterium sp.HPSCC05 derived from hypopharyngeal squamous cell carcinoma tissues is successfully separated, the strain has key technical attributes of stable growth, repeatable culture, clear preservation conditions and the like, and the problem of deficiency of current hypopharyngeal carcinoma related strains is solved. Fusobacteria sp.HPSCC05 is identified as a new fusobacterium species, and the blank of hypopharyngeal carcinoma tumor ecological niche specific strain resources is filled up. The method comprises the following steps: establishing an in-vitro verification model (fusobacterium-hypopharyngeal squamous carcinoma cell co-culture model) of the hypopharyngeal carcinoma promoting effect of the Fusobacterium sp.HPSCC05, and providing a replicable culture mode;

The invention discloses an application of an LAMP1 inhibitor in preparation of a medicine for preventing and / or treating esophageal cancer. Specifically, the application value of the LAMP1 inhibitor Parishin C in esophageal cancer treatment is found and verified for the first time, invasion and metastasis of esophageal squamous carcinoma cells and in-vivo lymph node metastasis can be remarkably inhibited by targeting LAMP1 protein and downstream signal channels of the LAMP1 protein and Parishin C, and a new drug choice is provided for metastatic esophageal cancer lacking effective treatment means clinically.

The application discloses radix sophorae tonkinensis polysaccharide STGP-1, a preparation method thereof and pharmaceutical use for treating lung squamous carcinoma, and relates to the technical field of medicines. The monosaccharide composition of STGP-1 includes fucose Fuc, arabinose Ara, galactose Gal, glucose Glc, xylose Xyl and mannose Man, and the molar ratio is 0.34:12.15:25.76:57.07:1.06:3.62. The STGP-1 is obtained by extraction, separation and purification from dried roots and rhizomes of radix sophorae tonkinensis, and the preparation method comprises the steps of pretreatment and crude extraction, impurity removal treatment, anion exchange column chromatography separation, gel column chromatography purification and the like. The STGP-1 can be used alone or in combination with anti-PD-1 monoclonal antibody for preparing a medicine for treating lung squamous carcinoma. The preparation process is stable, the source is natural, and the STGP-1 can provide a new high-efficiency and low-toxicity candidate medicine for immune combined treatment of lung squamous carcinoma.

The invention provides a lung squamous cell carcinoma organoid culture medium and a culture method. The lung squamous cell carcinoma organoid culture medium is prepared from the following components: R-spondin-1, Noggin, EGF (Epidermal Growth Factor), FGF10 (Fibroblast Growth Factor), FGF7 (Fibroblast Growth Factor), A83-01, Y-27632, Nicotinamide, Insulin, B27 Supplement, N-Acetylcysteine, Alpisib, GlutaMAX, primary cell antibiotics and the like. The lung squamous cell carcinoma organoid culture medium can be used for efficiently culturing lung squamous cell carcinoma tissues and successfully obtaining organoid, the formed organoid is highly similar to primary lung squamous cell carcinoma tissues in cell type, polarity and spatial hierarchical structure, and the micropathologic characteristics of tumors are truly reproduced. And the organoid can be stably passaged for a long time, so that an ideal and reliable preclinical model is provided for pathogenesis research, personalized drug screening and novel therapy development of lung squamous cell carcinoma.

The invention relates to a methylation site marker for assisting in early diagnosis of esophageal squamous cell carcinoma and application of the methylation site marker, and belongs to the technical field of biomedicine. The methylation site marker is one or a combination of human peripheral blood mononuclear cell methylation sites cg05064044, cg03395511 and cg21548813, and the nucleotide sequence of the methylation site marker is as shown in SEQ ID NO. 1-3. According to the present invention, the methylation chip detection results show that the methylation levels of the cg05064044, the cg03395511 and the cg21548813 in the peripheral blood mononuclear cells of the esophageal squamous cell carcinoma patient are significantly increased compared to the health control group; the methylation levels of cg05064044, cg03395511 and cg21548813 sites in PBMC of esophageal squamous cell carcinoma patients in a training queue and a verification queue are all obviously higher than those of a healthy control group through further analysis. Finally, through ROC curve analysis, it is determined that the three methylation sites cg05064044, cg03395511 and cg21548813 have good specificity and sensitivity, have high diagnosis efficiency when being independently or jointly used for esophageal squamous cell carcinoma diagnosis and can be used as potential molecular markers for esophageal squamous cell carcinoma diagnosis.

The invention discloses a marker LGALS9 for diagnosing nasopharyngeal squamous carcinoma and application thereof, and belongs to the technical field of molecular diagnosis. The invention finds that the LGALS9 molecule has significant high expression in nasopharyngeal squamous cell carcinoma tissues, prompts that the LGALS9 can be used as a unique marker for diagnosing the nasopharyngeal squamous cell carcinoma, further constructs a diagnosis model by taking the LGALS9 as the marker, preferably detects the expression level of the marker LGALS9 in the cancer tissues by adopting an immunohistochemical method, and unexpectedly finds that the LGALS9 molecule can be used for diagnosing the nasopharyngeal squamous cell carcinoma tissues. The diagnostic performance of the diagnostic model constructed according to an immunohistochemical detection result is superior to that of a model constructed by adopting a protein spectrum detection method. The marker LGALS9 and the diagnostic model provided by the invention provide technical support for tissue traceability of nasopharyngeal squamous carcinoma, and have great clinical transformation potential.

The invention discloses an esophageal squamous cell carcinoma noninvasive screening system based on a multi-marker saliva microbiome, and relates to the technical field of microorganisms and oncology, the key points of the technical scheme are as follows: the system comprises an input module, an analysis module and an output module, the input module inputs abundance change of specific flora of a saliva sample needing to be screened; the analysis module is used for analyzing the input saliva sample flora data; and the output module outputs the analysis result of the analysis module and judges whether the screened saliva sample owner belongs to the high-risk population of the esophageal squamous cell carcinoma patient. The abundance change of the specific flora of the saliva sample is obtained through metagenome sequencing or targeted PCR detection, and a microbial characteristic model is constructed to distinguish high-risk people. By means of the system, early-stage, non-invasive and high-acceptability screening of esophageal squamous carcinoma can be achieved.

The present invention provides a lung squamous cell carcinoma patient immunotherapy effect prediction device, which comprises a detection unit and a data analysis unit, the detection unit extracts 9 types of intra-tumor bacteria as characteristic intra-tumor bacteria based on 16S rRNA sequencing data of a lung squamous cell carcinoma patient tumor puncture sample; the data analysis unit is used for constructing a data model for predicting the curative effect of immunotherapy on the basis of 16S rRNA sequencing data of tumor puncture samples of the characteristic intra-tumor bacteria and lung squamous cell carcinoma patients; the characteristic intra-tumorous bacteria comprise a plasmobacterium actinomycetes genus, an anaerobic bacillus genus, a kantobacterium genus, a Vinci bacterium genus, a kocuria genus, a freshwater bacterium genus, a microbacterium genus, an achromobacter genus and a proteus genus; the prediction device can predict whether immunotherapy of lung squamous cell carcinoma patients is effective or not, screening and hierarchical management can be conducted on the patients before treatment, and therefore individualized medication is guided, and the curative effect is improved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of NLRC5 in targeted screening of medicines for improving immunotherapy of esophageal squamous carcinoma. NLRC5 expression is inhibited or regulated, and immunotherapy of esophageal squamous cell carcinoma is improved. The NLRC5 is highly methylated, and the expression of the NLRC5 in the ESCC is reduced. The NLRC5 is over-expressed, immune cell infiltration is promoted, meanwhile, immune escape is promoted by intensifying T cell depletion, immune checkpoint expression is up-regulated, and an immunosuppression state is created, so that anti-tumor immune response is potentially weakened. The invention discloses a polyhedral function of the NLRC5 in immune regulation and control from a single cell level, and particularly discloses close association of the NLRC5 with an immune checkpoint pathway and T cell depletion. A theoretical basis is provided for developing a therapy for targeting NLRC5, and a new way is possibly opened up for enhancing anti-tumor immune response. Researches show that NLRC5 is an important regulatory factor of immune response in ESCC, and plays a dual role in immune activation and immunosuppression.

The invention discloses an application of CDK5RAP2 protein in preparation of a kit for diagnosing neoadjuvant immunochemotherapy resistance of local advanced esophageal squamous carcinoma. Differential expression protein in neoadjuvant immunochemotherapy resistance tissues of local advanced esophageal squamous carcinoma is screened out through proteomics; a new marker is provided for diagnosis of local advanced esophageal squamous cell carcinoma immunochemotherapy drug resistance, and a basis is also provided for development and future development of a local advanced esophageal squamous cell carcinoma immunochemotherapy drug resistance diagnosis method.

The invention relates to a construction method and application of homologous mouse esophageal squamous carcinoma 3D (three-dimensional) organoids, and the construction method comprises the following specific steps: S1, inducing homologous mice to spontaneously form esophageal squamous carcinoma in situ by using a chemical carcinogen, and constructing a primary mouse esophageal squamous carcinoma model to obtain mouse esophageal squamous carcinoma tumor tissues; and S2, dissociating the mouse esophageal squamous cell carcinoma tumor tissue obtained in the step S1 into single cells, inoculating the single cells into an esophageal squamous cell carcinoma 3D organ amplification culture medium, and carrying out 3D culture to obtain the homologous mouse esophageal squamous cell carcinoma 3D organ. Compared with the prior art, the homologous mouse esophageal squamous cell carcinoma 3D organoid provided by the invention can realize stable proliferation and continuous passage, has very strong similarity with the structure and molecular biological characteristics of an in-situ tumor, and can better simulate the growth condition of the tumor in an in-vivo three-dimensional environment; a powerful experimental tool and a model platform are provided for research on the formation mechanism of the esophageal squamous cell carcinoma, targeted drug development and immunotherapy research.

The invention discloses a marker LGALS7 for diagnosing nasopharyngeal squamous cell carcinoma and application of the marker LGALS7, and belongs to the technical field of molecular diagnosis. Proteomics screening finds that LGALS7 is remarkably low in expression in nasopharyngeal squamous cell carcinoma tissues, which prompts that LGALS7 can be used as a biomarker for diagnosing nasopharyngeal squamous cell carcinoma. According to the invention, the diagnosis result obtained by detecting the LGALS7 by adopting an immunohistochemical method is higher in accuracy, and a support vector machine model is constructed based on the diagnosis result. A model evaluation result shows that the marker LGALS7 shows relatively high diagnosis specificity and sensitivity in a plurality of independent queues, squamous cell carcinoma from nasopharynx and squamous cell carcinoma from other parts can be effectively distinguished, and the problem of insufficient diagnosis specificity in the prior art is solved.

The invention discloses application of TCM cells in treatment of esophageal cancer. The application finds that the TCM cell can be used for treating esophageal cancer, especially esophageal squamous carcinoma for the first time, a new treatment means is provided for treating esophageal cancer, and the TCM cell has a wide clinical application prospect.

The invention relates to the technical field of biological medicines, in particular to application of a CA9 inhibitor in preparation of a medicine for preventing and treating esophageal squamous carcinoma. The invention provides an application of deoxidized labaquinone in preparation of a CA9 inhibitor, and further provides an application of deoxidized labaquinone or the CA9 inhibitor in preparation of a medicine for preventing and treating esophageal squamous cell carcinoma. According to the application, DEO can be used as a novel CA9 inhibitor, the effect of resisting esophageal squamous cell carcinoma is achieved by inducing alkali death, a brand new theoretical basis is provided for developing the novel inhibitor aiming at CA9 and clinical application of DEO, and the application has important theoretical value and wide clinical application prospects in efficient and low-toxicity treatment of esophageal squamous cell carcinoma.

The invention discloses a biomarker for predicting prognosis of esophageal squamous carcinoma and application of the biomarker, and relates to the technical field of biological medicines. The biomarker is tRF-24, and the nucleotide sequence of the biomarker is as shown in SEQ ID NO. 1. Researches find that the expression of tRF-24 in esophageal squamous cell carcinoma tumor tissues is obviously higher than that in para-carcinoma normal tissues, the expression quantity of late patients is obviously higher than that of early patients, and the higher the expression level is, the shorter the total lifetime of the patients is, and the poorer the prognosis is. Due to the characteristics, the tRF-24 can be used as one of important indexes for judging the clinical outcome of the esophageal squamous carcinoma patient. The invention proves that malignant progression of esophageal squamous carcinoma can be inhibited by reducing the expression quantity of tRF-24, which provides solid theoretical support and experimental basis for targeted therapy of tRF-24.

The invention discloses application of 3-bromo-1H-pyrrole-2, 5-diketone in preparation of a composition for treating esophageal squamous carcinoma, and is characterized in that the molecular formula of the 3-bromo-1H-pyrrole-2, 5-diketone is C4H2BrNO2, the molecular weight of the 3-bromo-1H-pyrrole-2, 5-diketone is 175.97, and the 3-bromo-1H-pyrrole-2, 5-diketone is derived from marine sponge Axinella brevista. The 3-bromo-1H-pyrrole-2, 5-diketone disclosed by the invention can effectively inhibit proliferation, migration, invasion and in-vivo tumor formation of esophageal squamous carcinoma cells, shows extremely low cytotoxicity, is remarkably superior to that of traditional chemotherapeutic drugs, and solves the technical problem that existing drugs for resisting esophageal squamous carcinoma are large in toxic and side effects.

The application relates to the fields of cell biology and biological medicine technology, and specifically discloses a kind of co-culture system construction method based on TGM2 target regulation mesenchymal stem cells and co-culture system prepared by the method. The method comprises the following steps: preparing human umbilical cord mesenchymal stem cells, lung adenocarcinoma cells A549 and lung squamous carcinoma cells SW1573 in logarithmic growth phase respectively; mixing A549 and SW1573 cells according to a 1:1 ratio to obtain mixed lung cancer cells; mixing hUC-MSC and mixed lung cancer cells according to a quantity ratio of 5:1 to 13:1, inoculating in a culture vessel containing culture medium, and culturing at 37 DEG C under a 5% CO2 condition for 3-9 days to obtain the co-culture system. The application does not need to genetically modify hUC-MSC, and by optimizing the co-culture ratio and time, using natural communication between cells, the proliferation, migration and invasion of lung cancer cells can be effectively inhibited, and cell cycle arrest and apoptosis can be induced.

This invention discloses a prognostic model and construction method for cervical squamous cell carcinoma, belonging to the fields of bioinformatics and oncology. The construction method is based on a set of genes related to programmed cell death, integrating multi-omics data of cervical squamous cell carcinoma patients from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and the Cancer Genome Characterization Project (CGCI). After standardized preprocessing, differential expression analysis, bootstrap resampling combined with univariate Cox regression for initial screening, consensus screening using multiple machine learning algorithms, and finally, multivariate Cox proportional hazards regression analysis to identify three core independent prognostic genes and construct a risk scoring model. This model has undergone multi-dimensional validation and optimization, demonstrating robust predictive performance. The method of this invention is standardized and highly reproducible, and the constructed model has high accuracy and strong generalization ability, providing a reliable tool for individualized prognostic assessment and clinical decision-making for cervical squamous cell carcinoma patients.

The invention provides a composition and a kit for oral squamous cell carcinoma typing and application of the composition and the kit, and particularly discloses the composition which comprises a fluorescent staining marker for CBX3 protein and a fluorescent staining marker for IL1RN protein. The invention also discloses a kit containing the composition. The kit and the composition can be used for oral squamous cell carcinoma typing, and prognosis and treatment sensitivity of a patient can be predicted according to a typing structure. The composition and the kit provided by the invention adopt a small amount of genes as classification and prediction indexes, so that the detection cost and the experiment complexity are greatly reduced. Through the established extremely simple classification rule, the expression quantity ratio of CBX3 to IL1RN only needs to be detected through the immunofluorescence technology, sample typing can be rapidly completed according to the condition that CBX3: IL1RN is larger than 1 or smaller than 1, complex biological information analysis is not needed, the detection process is visual and efficient, and the clinical diagnosis efficiency and accuracy can be effectively improved.